The optimal dosing of tasquinimod, Active Biotech’s experimental oral therapy for adults with relapsed or refractory multiple myeloma, has been determined in a Phase 1b/2a clinical trial. Now, that dose and schedule will be tested, along with the standard oral combination treatment, in the trial’s second phase, the company said in a press release. “We are pleased to have concluded the first part of this trial, confirming the previous safety profile of tasquinimod in patients…
You must be logged in to read/download the full post.
The post Optimal Dose of Tasquinimod Found in First Phase of RRMM Trial appeared first on BioNewsFeeds.